The Experts below are selected from a list of 1446 Experts worldwide ranked by ideXlab platform
Wang Dong - One of the best experts on this subject based on the ideXlab platform.
-
Clinical effects of Nedaplatin,Tegafur Gimeracil Oteracil Potassium capsule combined with three-dimensional conformal radiotherapy in elderly patients with locally advanced non-small cell lung cancer
Journal of Hainan Medical University, 2012Co-Authors: Wang DongAbstract:Objective: To investigate the clinical effects and safety of Nedaplati,Tegafur Gimeracil Oteracil Potassium capsule combined with three-dimensional conformal radiotherapy in elderly patients with locally advanced non-small cell lung cancer.Methods: A total of 50 elderly patients with locally advanced non-small cell lung cancer that were treated in our hospital from January 2010 to January 2011 were selected and randomly divided into control group(only three-dimensional conformal radiotherapy group)and observation group(Nedaplatin,Tegafur Gimeracil Oteracil Potassium Capsule combined with three-dimensional conformal radiotherapy group)with 25 cases in each group,then the total effective rate,clinical benefit rate,progression-free survival,one-year survival rate and adverse reactions of two groups were compared.Results:The total effective rate and clinical benefit rate of observation group were 88.00% and 96.00%,and they were significant higher than 56.00% and 84.00% of observation group,progression-free survival time of the observation group was(17.5±1.8)months,significant longer than(11.9±1.3)months of the control group,one-year survival rate was 72.00%,and it was higher than 48.00% of control group(P0.05).Hematological toxicity of the observation group was higher than that of control group(P0.05).However,the rates of radioactive esophagitis and radiation pneumonitis of two groups was not significantly different(P0.05).Conclusion:The clinical effects and safety of Nedaplatin,Tegafur Gimeracil Oteracil Potassium Capsule combined with three-dimensional conformal radiotherapy in the treatment of elderly patients with locally advanced non-small cell lung cancer is better,and the adverse reactions is tolerable.
Susumu Kodaira - One of the best experts on this subject based on the ideXlab platform.
-
Adjuvant chemotherapy with uracil-Tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol
2014Co-Authors: Takayuki Akasu, Yoshihiro Moriya, Yasuo Ohashi, Shigeaki Yoshida, Kuniaki Shirao, Susumu Kodaira, National Surgical, Adjuvant Study, Colorectal CanceryAbstract:Background: Although adjuvant radiotherapy was proved to be effective for local control of rectal cancer even after standardized mesorectal excision, the role of adjuvant chemotherapy after such standardized surgery remains to be clarified. We aimed to assess the efficacy of a combination of uracil and Tegafur for pathological stage III rectal cancer treated by standardized mesorectal excision with selective lateral pelvic lymphadenectomy. Methods: We randomly assigned patients with completely resected stage III rectal cancer, who underwent standardized mesorectal excision with selective lateral pelvic lymphadenectomy, to receive either oral uracil–Tegafur (400 mg/m2 Tegafur per day) for one year or no treatment. Standardization and quality control of the surgery and pathological techniques were ensured by use of the guidelines of the Japanese Society for Cancer of the Colon and Rectum. The primary endpoint was relapse-free survival. The secondary endpoint was overall survival. Results: We enrolled and randomized 276 patients. Excluding two ineligible patients, 274 were included in the analysis. Planned interim analysis 2 years after accrual termination revealed significant prolongation of relapse-free survival (P = 0.001) and overall survival (P = 0.005) in the uracil–Tegafur group. The 3-year relapse-free survival and overall survival rates were 7
-
adjuvant chemotherapy with uracil Tegafur for pathological stage iii rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy a multicenter randomized controlled trial
Japanese Journal of Clinical Oncology, 2006Co-Authors: Takayuki Akasu, Yoshihiro Moriya, Yasuo Ohashi, Shigeaki Yoshida, Kuniaki Shirao, Susumu KodairaAbstract:Background: Although adjuvant radiotherapy was proved to be effective for local control of rectal cancer even after standardized mesorectal excision, the role of adjuvant chemotherapy after such standardized surgery remains to be clarified. We aimed to assess the efficacy of a combination of uracil and Tegafur for pathological stage III rectal cancer treated by standardized mesorectal excision with selective lateral pelvic lymphadenectomy. Methods: We randomly assigned patients with completely resected stage III rectal cancer, who underwent standardized mesorectal excision with selective lateral pelvic lymphadenectomy, to receive either oral uracil–Tegafur (400 mg/m 2 Tegafur per day) for one year or no treatment. Standardization and quality control of the surgery and pathological techniques were ensured by use of the guidelines of the Japanese Society for Cancer of the Colon and Rectum. The primary endpoint was relapse-free survival. The secondary endpoint was overall survival. Results: We enrolled and randomized 276 patients. Excluding two ineligible patients, 274 were included in the analysis. Planned interim analysis 2 years after accrual termination revealed significant prolongation of relapse-free survival (P = 0.001) and overall survival (P = 0.005) in the uracil–Tegafur group. The 3-year relapse-free survival and overall survival rates were 78 and 91% in the chemotherapy group and 60 and 81% in the surgery-alone group, respectively. Local recurrence rates were low in both groups. Grade 3 events occurred in 17% of the chemotherapy patients, but no grade 4 or more events occurred. Conclusion: Adjuvant chemotherapy with uracil–Tegafur improves survival of patients with stage III rectal cancer after standardized mesorectal excision with selective lateral pelvic lymphadenectomy.
-
postoperative adjuvant chemotherapy with mitomycin c and uft for curatively resected rectal cancer results from the cooperative project no 7 group of the japanese foundation for multidisciplinary treatment of cancer
International Journal of Clinical Oncology, 1998Co-Authors: Susumu Kodaira, K Kikuchi, Y Kunii, Masayuki Yasutomi, Takashi Takahashi, K Hojo, Tomoyuki Kato, T TominagaAbstract:Background. This study was conducted to evaluate the significance of postoperative adjuvant chemotherapy using mitomycin C (MMC) and UFT (Tegafur; uracil at 1:4 molar ratio) in combination for rectal cancer.
Jia-hong Chen - One of the best experts on this subject based on the ideXlab platform.
-
Overall survival of the UFUR group vs. the comparison group.
2017Co-Authors: Wen-yen Huang, Chia-cheng Lee, Cheng-wen Hsiao, Shu-wen Jao, Jen-fu Yang, Jia-hong ChenAbstract:5-year OS: 86.8% vs. 68.5%, p = 0.01. UFUR: Tegafur-uracil.
-
Disease-free survival of the UFUR group vs. the comparison group.
2017Co-Authors: Wen-yen Huang, Chia-cheng Lee, Cheng-wen Hsiao, Shu-wen Jao, Jen-fu Yang, Jia-hong ChenAbstract:5-year DFS: 69.1% vs. 62.3%, p = 0.21. UFUR: Tegafur-uracil.
-
Univariate Cox regression analysis of 4-year progression-free survival and overall survival of 180 patients with age
2015Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong ChenAbstract:a. only oral regimens: XELODA and UFUR groups;b. combined regimens: FOLFOX, XELOX, OXA then 5-FU and FL groups.Abbreviations: 4-y OS: 4-year overall survival; 4-y PFS: 4-year progression-free survival; 95% CI: 95% confidence interval; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; OXA: oxaliplatin; OXA then 5-FU: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral Tegafur-uracil/folinate calcium or oral capecitabine); P: probability value; RR: relative risk; UFUR: oral UFUR/LV, Tegafur-uracil/oral folinate calcium (leucovorin); vs: versus; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.
-
Univariate Cox regression analysis of 4-year progression-free survival and overall survival of 108 patients with with old age (≧70) in relation to chemotherapeutic strategies.
2015Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong ChenAbstract:a. only oral regimens: XELODA and UFUR groups;b. combined regimens: FOLFOX, XELOX, OXA then 5-FU and FL groups.Abbreviations: 4-y OS: 4-year overall survival; 4-y PFS: 4-year progression-free survival; 95% CI: 95% confidence interval; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; OXA: oxaliplatin; OXA then 5-FU: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral Tegafur-uracil/folinate calcium or oral capecitabine); P: probability value; RR: relative risk; UFUR: oral UFUR/LV, Tegafur-uracil/oral folinate calcium (leucovorin); vs: versus; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.
-
The descriptive characteristics and distribution of patients according to chemoregimens.
2015Co-Authors: Ping-ying Chang, Yu-guang Chen, Jia-hong ChenAbstract:Abbreviations: CEA: carcinoembryonic antigen; ECOG: Eastern Cooperative Oncology Group performance status; FL: 5-Fluorouracil (5-FU)/leucovorin; FOLFOX: mFOLFOX 6, 5-FU/leucovorin/oxaliplatin; LNR: the positive lymph node ratio of dissected lymph nodes; No.: number; OXA-based+ 5-FU-based: Oxaliplatin-based chemotherapy (less than 8 cycles of 5-FU/leucovorin/oxaliplatin or less than 6 cycles of oral capecitabine/intravenous oxaliplatin) followed by 5-FU-based chemotherapy (5-FU/leucovorin, oral Tegafur-uracil/folinate calcium or oral capecitabine); P: probability value; TNM stage: Cancer staging system which was developed and is maintained by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) is based on the extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M); UFUR: oral UFUR/LV, Tegafur-uracil/oral folinate calcium (leucovorin); w/o: without; XELODA: oral capecitabine; XELOX: CapeOx, oral capecitabine/intravenous oxaliplatin; y/o: years old.
Yasuo Ohashi - One of the best experts on this subject based on the ideXlab platform.
-
Adjuvant chemotherapy with uracil-Tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol
2014Co-Authors: Takayuki Akasu, Yoshihiro Moriya, Yasuo Ohashi, Shigeaki Yoshida, Kuniaki Shirao, Susumu Kodaira, National Surgical, Adjuvant Study, Colorectal CanceryAbstract:Background: Although adjuvant radiotherapy was proved to be effective for local control of rectal cancer even after standardized mesorectal excision, the role of adjuvant chemotherapy after such standardized surgery remains to be clarified. We aimed to assess the efficacy of a combination of uracil and Tegafur for pathological stage III rectal cancer treated by standardized mesorectal excision with selective lateral pelvic lymphadenectomy. Methods: We randomly assigned patients with completely resected stage III rectal cancer, who underwent standardized mesorectal excision with selective lateral pelvic lymphadenectomy, to receive either oral uracil–Tegafur (400 mg/m2 Tegafur per day) for one year or no treatment. Standardization and quality control of the surgery and pathological techniques were ensured by use of the guidelines of the Japanese Society for Cancer of the Colon and Rectum. The primary endpoint was relapse-free survival. The secondary endpoint was overall survival. Results: We enrolled and randomized 276 patients. Excluding two ineligible patients, 274 were included in the analysis. Planned interim analysis 2 years after accrual termination revealed significant prolongation of relapse-free survival (P = 0.001) and overall survival (P = 0.005) in the uracil–Tegafur group. The 3-year relapse-free survival and overall survival rates were 7
-
randomized controlled trial of adjuvant uracil Tegafur versus surgery alone for serosa negative locally advanced gastric cancer
British Journal of Surgery, 2007Co-Authors: Toshifusa Nakajima, Taira Kinoshita, Atsushi Nashimoto, Motonori Sairenji, Toshiharu Yamaguchi, Junichi Sakamoto, T Fujiya, T Inada, Mitsuru Sasako, Yasuo OhashiAbstract:Background: This prospective randomized study compared the survival of patients with tumour node metastasis (TNM) stage T2 N1–2 gastric cancer treated by gastrectomy alone or gastrectomy followed by uracil–Tegafur. Methods: Patients were randomly assigned to surgery alone or to surgery and postoperative uracil–Tegafur 360 mg per m2 per day orally for 16 months. The primary endpoint was overall survival. Relapse-free survival and site of recurrence were secondary endpoints. Results: Of 190 registered patients, 95 were randomized to each group; two patients with early cancer were subsequently excluded from the chemotherapy group. The trial was terminated before the target number of patients was reached because accrual was slower than expected. Drug-related adverse effects were mild, with no treatment-related deaths. At a median follow-up of 6·2 years, overall and relapse-free survival rates were significantly higher in the chemotherapy group (hazard ratio for overall survival 0·48, P = 0·017; hazard ratio for relapse-free survival 0·44, P = 0·005), confirming the survival benefit shown in an interim analysis performed 2 years earlier. Conclusion: Interim and final analyses revealed a significant survival benefit for postoperative adjuvant chemotherapy with uracil–Tegafur in patients with serosa-negative, node-positive gastric cancer. Registration number: NCT00152243 (http://www.clinicaltrials.gov). Copyright © 2007 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
-
adjuvant chemotherapy with uracil Tegafur for pathological stage iii rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy a multicenter randomized controlled trial
Japanese Journal of Clinical Oncology, 2006Co-Authors: Takayuki Akasu, Yoshihiro Moriya, Yasuo Ohashi, Shigeaki Yoshida, Kuniaki Shirao, Susumu KodairaAbstract:Background: Although adjuvant radiotherapy was proved to be effective for local control of rectal cancer even after standardized mesorectal excision, the role of adjuvant chemotherapy after such standardized surgery remains to be clarified. We aimed to assess the efficacy of a combination of uracil and Tegafur for pathological stage III rectal cancer treated by standardized mesorectal excision with selective lateral pelvic lymphadenectomy. Methods: We randomly assigned patients with completely resected stage III rectal cancer, who underwent standardized mesorectal excision with selective lateral pelvic lymphadenectomy, to receive either oral uracil–Tegafur (400 mg/m 2 Tegafur per day) for one year or no treatment. Standardization and quality control of the surgery and pathological techniques were ensured by use of the guidelines of the Japanese Society for Cancer of the Colon and Rectum. The primary endpoint was relapse-free survival. The secondary endpoint was overall survival. Results: We enrolled and randomized 276 patients. Excluding two ineligible patients, 274 were included in the analysis. Planned interim analysis 2 years after accrual termination revealed significant prolongation of relapse-free survival (P = 0.001) and overall survival (P = 0.005) in the uracil–Tegafur group. The 3-year relapse-free survival and overall survival rates were 78 and 91% in the chemotherapy group and 60 and 81% in the surgery-alone group, respectively. Local recurrence rates were low in both groups. Grade 3 events occurred in 17% of the chemotherapy patients, but no grade 4 or more events occurred. Conclusion: Adjuvant chemotherapy with uracil–Tegafur improves survival of patients with stage III rectal cancer after standardized mesorectal excision with selective lateral pelvic lymphadenectomy.
Masafumi Kawamura - One of the best experts on this subject based on the ideXlab platform.
-
spinal infarction related to the adjuvant chemotherapy for surgically resected non small cell lung cancer report of a case
Japanese Journal of Clinical Oncology, 2013Co-Authors: Noriyuki Matsutani, Masafumi KawamuraAbstract:We report the development of spinal infarction during adjuvant chemotherapy with Tegafur, gimeracil and oteracil (TS-1) after surgery for lung adenocarcinoma. A 69-year-old female had a left upper lobectomy for pulmonary adenocarcinoma, T2aN0M0. Six weeks after the surgery, Tegafur, gimeracil and oteracil were administered orally as adjuvant chemotherapy for 1 year. After 10 months of adjuvant chemotherapy, the patient suddenly showed signs of numbness and weakness in both lower limbs. The patient did not have a previous medical history, and was receiving only Tegafur, gimeracil and oteracil with the stomach medication. Neurological findings showed muscle weakness, numbness and a loss of tendon reflex in both lower limbs, as well as bladder and rectal disturbance. Blood tests, brain magnetic resonance imaging and chest computed tomography showed no signs of abnormalities or metastasis. Magnetic resonance imaging of the spine showed a hyperintense lesion between the Th12 and L1 spinal levels by T2-weighted image. A spinal fluid test indicated no abnormalities, and cytological diagnosis was class II. Anti-aquaporin 4, anti-ganglioside and anti-neuronal autoantibodies were all negative. These results indicated that the patient had a spinal infarction, rather than myelitis or paraneoplastic neurological syndrome. The patient was treated with heparin and steroid pulse treatment followed by rehabilitation, and recovered sufficiently to be able to walk using a cane after 2 months. The development of spinal infarction during anti-cancer chemotherapy has not been previously reported. In this case, an association of spinal infarction with the use of adjuvant chemotherapy was strongly indicated due to the lack of abnormalities in coagulability, atherosclerotic lesions and aortic disease.
-
Spinal Infarction Related to the Adjuvant Chemotherapy for Surgically Resected Non-small Cell Lung Cancer: Report of a Case
2012Co-Authors: Noriyuki Matsutani, Masafumi KawamuraAbstract:We report the development of spinal infarction during adjuvant chemotherapy with Tegafur, gimeracil and oteracil (TS-1) after surgery for lung adenocarcinoma. A 69-year-old female had a left upper lobectomy for pulmonary adenocarcinoma, T2aN0M0. Six weeks after the surgery, Tegafur, gimeracil and oteracil were administered orally as adjuvant chemotherapy for 1 year. After 10 months of adjuvant chemotherapy, the patient suddenly showed signs of numbness and weakness in both lower limbs. The patient did not have a previous medical history, and was receiving only Tegafur, gimeracil and oteracil with the stomach medication. Neurological findings showed muscle weakness, numbness and a loss of tendon reflex in both lower limbs, as well as bladder and rectal disturbance. Blood tests, brain magnetic res-onance imaging and chest computed tomography showed no signs of abnormalities or metas-tasis. Magnetic resonance imaging of the spine showed a hyperintense lesion between the Th12 and L1 spinal levels by T2-weighted image. A spinal fluid test indicated no abnormal-ities, and cytological diagnosis was class II. Anti-aquaporin 4, anti-ganglioside and anti-neur-onal autoantibodies were all negative. These results indicated that the patient had a spinal infarction, rather than myelitis or paraneoplastic neurological syndrome. The patient wa
-
Case Report Spinal Infarction Related to the Adjuvant Chemotherapy for Surgically Resected Non-small Cell Lung Cancer: Report of a Case
2012Co-Authors: Noriyuki Matsutani, Masafumi KawamuraAbstract:We report the development of spinal infarction during adjuvant chemotherapy with Tegafur, gimeracil and oteracil (TS-1) after surgery for lung adenocarcinoma. A 69-year-old female had a left upper lobectomy for pulmonary adenocarcinoma, T2aN0M0. Six weeks after the surgery, Tegafur, gimeracil and oteracil were administered orally as adjuvant chemotherapy for 1 year. After 10 months of adjuvant chemotherapy, the patient suddenly showed signs of numbness and weakness in both lower limbs. The patient did not have a previous medical history, and was receiving only Tegafur, gimeracil and oteracil with the stomach medication. Neurological findings showed muscle weakness, numbness and a loss of tendon reflex in both lower limbs, as well as bladder and rectal disturbance. Blood tests, brain magnetic res-onance imaging and chest computed tomography showed no signs of abnormalities or metas-tasis. Magnetic resonance imaging of the spine showed a hyperintense lesion between the Th12 and L1 spinal levels by T2-weighted image. A spinal fluid test indicated no abnormal-ities, and cytological diagnosis was class II. Anti-aquaporin 4, anti-ganglioside and anti-neur-onal autoantibodies were all negative. These results indicated that the patient had a spinal infarction, rather than myelitis or paraneoplastic neurological syndrome. The patient wa
